Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 16 Issue 2, June 2022

In this issue...

• Small-molecule drug discovery accelerated by artificial intelligence

• Infectious disease dealmaking refocuses

• The rise of targeted protein degradation

• RNAi therapeutics back on the menu

3D illustration concept of a cybernetic brain combining deep machine learning and artificial intelligence. Skorzewiak / Alamy Stock Photo.

Artificial intelligence makes a splash in small-molecule drug discovery

Top of page ⤴

From drug target inhibition to degradation: a TACtical strategy

Top of page ⤴

Buy buy RNAi

  • Feature

    • With siRNA-based drugs becoming established as a therapeutic modality, large companies are engaging in the field through deals and acquisitions, and cardiovascular and metabolic diseases are among their targets.

      • Biopharma Dealmakers
      News Feature
  • Profiles

    • EraCal Therapeutics is developing a novel oral-active anti-obesity drug, Era-379, identified using the company’s state-of-the-art, zebrafish-based platform technology. EraCal is raising a series A to generate human proof-of-concept data for Era-379 and expanding its portfolio through co-development partnerships.

      • EraCal Therapeutics Ltd.
      Advertisement Feature
    • Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with the gut wall to treat metabolic and chronic conditions. The company’s lead candidate, GLY-200, is advancing into phase 2 clinical studies for the treatment of type 2 diabetes.

      • Glyscend, Inc.
      Advertisement Feature
Top of page ⤴

Search

Quick links